Integrated Environmental Technologies 10-Q 16 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 13, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	INTEGRATED ENVIRONMENTAL TECHNOLOGIES, LTD.
Entity Central Index Key	1,084,031
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		320,571,243
Trading Symbol	IEVM
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,016

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 274,542	$ 838,107
Accounts receivable, net	35,261	36,223
Prepaid expenses and other	10,057	14,948
Inventory	100,918	103,220
Total current assets	420,778	992,498
Property and equipment, net	228,227	245,621
Total assets	649,005	1,238,119
Current liabilities:
Accounts payable	341,053	209,774
Accrued expenses	220,299	199,893
Customer deposits	2,000	2,000
Convertible debentures	501,125	501,125
Total current liabilities	1,064,477	912,792
Convertible debentures	815,605	788,501
Total liabilities	1,880,082	1,701,293
Stockholders’ deficiency:
Common stock, $.001 par value; 600,000,000 shares authorized; 311,404,576 shares issued and outstanding	311,405	311,405
Additional paid-in capital	24,006,704	24,005,008
Accumulated deficit	(25,549,186)	(24,779,587)
Total stockholders’ deficiency	(1,231,077)	(463,174)
Total liabilities and stockholders’ deficiency	$ 649,005	$ 1,238,119

Consolidated Condensed Balance3

Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value	$ .001	$ 0.001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	311,404,576	311,404,576
Common stock, shares outstanding	311,404,576	311,404,576

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Sales	$ 27,798	$ 144,077
Leasing and licensing fees	6,000	6,000
Total revenues	33,798	150,077
Cost of sales	14,258	56,430
Gross profit	19,540	93,647
Operating expenses:
General and administrative	276,775	587,709
Sales and marketing	387,685	422,682
Research and development	57,369	134,010
Total operating expenses	721,829	1,144,401
Loss from operations	(702,289)	(1,050,754)
Other income (expense):
Interest income	73	120
Interest expense	(67,383)	(11,011)
Total other income (expense)	(67,310)	(10,891)
Net loss	$ (769,599)	$ (1,061,645)
Net loss per share, basic and diluted	$ 0	$ 0
Weighted average shares outstanding, basic and diluted	311,404,576	279,195,053

Consolidated Condensed Stateme5

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (769,599)	$ (1,061,645)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	22,745	22,608
Stock-based compensation expense	1,696	$ 375,088
Interest accreted on convertible debentures	27,104
Changes in operating assets and liabilities:
Accounts receivable	191	$ (59,441)
Inventory	2,302	(2,267)
Prepaid expenses and other	$ 4,891	(7,967)
Other receivable		111,200
Accounts payable	$ 132,050	101,319
Accrued expenses	20,406	(100,210)
Net cash used in operating activities	(558,214)	(621,315)
Cash flows used in investing activity:
Purchase of equipment	$ (5,351)	(15,052)
Cash flows from financing activities:
Proceeds from sale of common stock, net of offering costs		1,913,950
Repayment of note payable		(19,717)
Net cash provided by financing activities		1,894,233
(Decrease) increase in cash	$ (563,565)	1,257,866
Cash - beginning of period	838,107	371,292
Cash - end of period	274,542	1,629,158
Supplemental disclosure of cash flow information:
Cash paid for interest	320	6,909
Cash paid for income taxes	$ 650	900
Issuance of 1,055,303 shares of common stock as payment of offering costs related to private placements		56,000
Issuance of warrants to purchase 1,450,303 shares of common stock as payment of offering costs related to private placements		$ 47,100

Consolidated Condensed Stateme6

Consolidated Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Cash Flows [Abstract]
Common stock issued as payment offering costs related to private placements	1,055,303	1,055,303
Issuance of warrant to purchase of common stock shares as payment of offering costs related to private placements	1,450,303	1,450,303

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying consolidated condensed financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant recurring operating losses and negative cash flows from operations. The Company had a working capital deficiency of $643,699 and an accumulated deficit of $25,549,186 as of March 31, 2016. The Company also has no lending relationships with commercial banks and is dependent on the completion of financings involving the private placement of its securities in order to continue operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company does not anticipate establishing any lending relationships with commercial banks in the foreseeable future due to its unprofitable operations and limited assets. The Company continues to execute its strategy of selling Excelyte ® ™

Inventory

Inventory	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventory	2. Inventory As of March 31, 2016 and December 31, 2015, inventory consisted of parts and materials totaling $100,918 and $103,220, respectively.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	3. Property and Equipment As of March 31, 2016 and December 31, 2015, property and equipment, on a net basis, consisted of the following: March 31, 2016 December 31, 2015 Leasehold improvements $ 328,977 $ 328,977 Equipment 520,658 515,307 849,635 844,284 Less: Accumulated depreciation (621,408 ) (598,663 ) $ 228,227 $ 245,621

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2016
Payables and Accruals [Abstract]
Accrued Expenses	4. Accrued Expenses As of March 31, 2016 and December 31, 2015, accrued expenses consisted of the following: March 31, 2016 December 31, 2015 Accrued compensation $ 116,455 $ 116,455 Accrued interest (see Note 5) 79,267 39,188 Accrued professional fees 2,750 22,000 Accrued consulting fees and other expenses 21,827 22,250 $ 220,299 $ 199,893

Convertible Debentures

Convertible Debentures	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Convertible Debentures	5. Convertible Debentures April 2007 Convertible Debenture On April 26, 2007, the Company issued a convertible debenture to an individual investor in the principal amount of $25,000. This convertible debenture matured on January 2, 2009 and remains unpaid and, as a result, such obligation can be placed in default by the holder. The convertible debenture accrues interest at a rate of 12% per annum and is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.40 per share. An aggregate of 62,500 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on this convertible debenture at the current conversion price of $0.40 per share. During the three months ended March 31, 2016 and 2015, the Company recorded a total of $748 and $740, respectively, of interest expense related to this convertible debenture. As of March 31, 2016 and December 31, 2015, the outstanding principal on this convertible debenture was $25,000, which was included as a component of current convertible debentures, and the accrued and unpaid interest was $17,189 and $16,441, respectively, which was included as a component of accrued expenses (see Note 4). Zanett Convertible Debenture On August 21, 2012, the Company issued to Zanett Opportunity Fund, Ltd. an 8% convertible debenture in the amount of $476,125 (the “Zanett August 2012 Debenture”). The Zanett August 2012 Debenture has a three-year term maturing on August 21, 2015 and bears interest at a rate of 8% per annum. An aggregate of 4,761,250 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on the Zanett August 2012 Debenture. The Company has not made payment on the outstanding balance due on the Zanett August 2012 Debenture and, as a result, such obligation can be placed in default by the holder. During the three months ended March 31, 2016 and 2015, the Company recorded $9,496 and $9,392, respectively, of interest expense related to the Zanett August 2012 Debenture. As of March 31, 2016 and December 31, 2015, the outstanding principal on the Zanett August 2012 Debenture was $476,125, which was included as a component of current convertible debentures, and the accrued and unpaid interest was $23,376 and $13,880, respectively, which was included as a component of accrued expenses (see Note 4). November and December 2015 Convertible Debentures and Warrants On November 11, 2015, December 3, 2015 and December 18, 2015, the Company issued 12% convertible debentures (the “2015 Debentures”) in the aggregate principal amount of $997,222 to five institutional investors and three individual investors. In connection with the issuance of the 2015 Debentures, the Company issued warrants (the “2015 Debenture Warrants”) to purchase an aggregate of 7,123,014 shares of its common stock. The gross proceeds received in connection with these private placements were $897,500. The 2015 Debentures mature on the date that is two years from the issuance date, bear interest at a rate of 12% per annum and contain an original issue discount of 10% of the principal amount ($99,722 in aggregate). The entire principal amount of each of the 2015 Debentures is convertible at any time into shares of the Company’s common stock at the option of the respective debenture holder at a conversion price of $0.07 per share. An aggregate of 14,246,029 shares of the Company’s common stock can be issued pursuant to the 2015 Debentures at the current conversion price of $0.07 per share. The Company separately accounted for the liability and equity components of the 2015 Debentures based upon the relative fair value of the liability and equity components on the respective dates of issuance. As a result, the Company recorded a discount of $117,708 for the 2015 Debentures to account for the relative fair value attributable to the 2015 Debenture Warrants, which is being accreted as interest expense using the effective interest method over the respective two-year terms of each of the 2015 Debentures. In addition, the $99,722 original issue discount is also being accreted as interest expense using the effective interest method over the respective two-year terms of each of the 2015 Debentures. For the three months ended March 31, 2016, the Company recorded a total of $56,939 ($27,104 accreted) of interest expense related to the 2015 Debentures. As of March 31, 2016 and December 31, 2015, $38,702 and $8,867, respectively, of interest due on the 2015 Debentures was accrued and recorded as a component of accrued expenses (see Note 4). As of March 31, 2016, the unamortized discount on the 2015 Debentures related to the fair value of the 2015 Debenture Warrants was $98,021, the unamortized discount on the 2015 Debentures related to the original issue discount was $83,596 and the net carrying value of the 2015 Debentures was $815,605, which was recorded as a component of non-current convertible debentures. As of December 31, 2015, the net carrying value of the 2015 Debentures was $788,501, which was recorded as a component of non-current convertible debentures.

Stockholders' Deficiency

Stockholders' Deficiency	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders' Deficiency	6.Stockholders’ Deficiency Stock Options The Company currently has two stock option/stock compensation plans in place: the 2010 Stock Incentive Plan and the 2012 Equity Incentive Plan (collectively, the “Equity Incentive Plans”). The 2010 Stock Incentive Plan was approved by the stockholders in September 2010. The Company had reserved for issuance an aggregate of 10,000,000 shares of common stock under the 2010 Stock Incentive Plan. As of March 31, 2016, stock options to purchase 3,846,920 shares of the Company’s common stock were outstanding under the 2010 Stock Incentive Plan and 90,500 shares of the Company’s common stock had been issued under the 2010 Stock Incentive Plan. As a result of the adoption of the Company’s 2012 Equity Incentive Plan, no further awards are permitted under the 2010 Stock Incentive Plan. The 2012 Equity Incentive Plan was approved by the stockholders in May 2012. The original aggregate number of shares of common stock which could be awarded under the 2012 Equity Incentive Plan was 14,000,000 shares, subject to adjustment as provided in the 2012 Equity Incentive Plan. Effective January 29, 2016, as permitted under the 2012 Equity Incentive Plan, the Company’s board of directors increased the number of shares of common stock that could be awarded under the 2012 Equity Incentive Plan to 31,140,458 shares. As of March 31, 2016, options to purchase 2,518,150 shares of the Company’s common stock were outstanding under the 2012 Equity Incentive Plan and up to 28,622,308 shares of the Company’s common stock remain available for awards under the 2012 Equity Incentive Plan. Common stock grants and stock option awards under the Equity Incentive Plans were granted or issued at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company’s common stock on the date of grant or issuance. Stock options granted and outstanding to date consist of both incentive stock options and non-qualified stock options. A summary of stock option transactions under the Equity Incentive Plans during the three months ended March 31, 2016 is set forth below: Stock Option Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2015 8,365,070 $ 0.11 $ — Granted during the period — — — Exercised during the period — — — Terminated during the period (2,000,000 ) $ 0.04 — Outstanding at March 31, 2016 6,365,070 $ 0.13 $ — Exercisable at March 31, 2016 6,115,070 $ 0.13 $ — Exercisable at December 31, 2015 6,002,570 $ 0.13 $ — Information with respect to stock options outstanding and stock options exercisable as of March 31, 2016 is as follows: Stock Options Outstanding Stock Options Exercisable Exercise Price Number of Shares Available Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) Number of Shares Available for Purchase Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) $ 0.07 2,068,150 $ 0.07 4.0 2,068,150 $ 0.07 4.0 $ 0.08 450,000 $ 0.08 8.9 200,000 $ 0.08 8.9 $ 0.10 2,180,253 $ 0.10 2.9 2,180,253 $ 0.10 2.9 $ 0.20 833,333 $ 0.20 6.0 833,333 $ 0.20 6.0 $ 0.30 833,334 $ 0.30 6.0 833,334 $ 0.30 6.0 6,365,070 $ 0.13 4.5 6,115,070 $ 0.13 4.3 A summary of the non-vested shares subject to stock options granted under the Equity Incentive Plans as of March 31, 2016 is as follows: Stock Option Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2015 2,362,500 $ 0.03 Granted during the period — — Vested during the period (112,500 ) $ 0.05 Terminated during the period (2,000,000 ) $ 0.03 Non-vested at March 31, 2016 250,000 $ 0.05 As of March 31, 2016, there was $14,212 of total unrecognized compensation cost related to non-vested, stock-based compensation arrangements granted under the Equity Incentive Plans. That cost is expected to be recognized over a weighted average period of twenty-six months. Warrants to Purchase Common Stock A summary of warrant transactions during the three months ended March 31, 2016 is as follows: Warrant Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2015 25,454,701 $ 0.08 $ 3,459 Issued during the period — — — Exercised during the period — — — Terminated during the period (500,000 ) $ 0.04 — Outstanding at March 31, 2016 24,954,701 $ 0.08 $ — Exercisable at March 31, 2016 24,954,701 $ 0.08 $ — Exercisable at December 31, 2015 25,454,701 $ 0.08 $ 3,459 Warrants issued by the Company contain exercise prices that were approved by the Company’s board of directors. Such exercise prices are generally not less than the quoted market price of the Company’s common stock on the date of issuance. Warrants currently issued either vested immediately or over a period of up to three years and have a maximum term of ten years from the date of issuance. Information with respect to warrants outstanding and warrants exercisable at March 31, 2016 is as follows: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number of Shares Available Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share Number of Shares Available for Purchase Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share $ 0.03 - 0.04 1,167,442 2.0 $ 0.04 1,167,442 2.0 $ 0.04 $ 0.06 - 0.07 10,344,244 3.2 $ 0.07 10,344,244 3.2 $ 0.07 $ 0.08 - 0.10 13,443,015 3.8 $ 0.10 13,443,015 3.8 $ 0.10 24,954,701 3.5 $ 0.08 24,954,701 3.5 $ 0.08 As of March 31, 2016, there were no non-vested shares subject to warrants and no unrecognized compensation cost related to warrants.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation During the three months ended March 31, 2016 and 2015, the Company recorded stock-based compensation expense as follows: Three Months Ended March 31, 2016 2015 General and administrative $ 299 $ 187,357 Sales and marketing 1,397 131,554 Research and development — 56,177 $ 1,696 $ 375,088 For the three months ended March 31, 2016 and 2015, the Company recorded stock-based compensation expense related to common stock and stock options granted to employees and directors of $1,696 and $375,088, respectively. For the three months ended March 31, 2016 and 2015, the Company did not record any stock-based compensation expense for non-employees.

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2016
Net Loss Per Common Share
Net Loss Per Common Share	8. Net Loss Per Common Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method. For the three months ended March 31, 2016, diluted net loss per share did not include the effect of 6,365,070 shares of common stock issuable upon the exercise of outstanding stock options, 24,954,701 shares of common stock issuable upon the exercise of outstanding warrants and 19,069,779 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive. For the three months ended March 31, 2015, diluted net loss per share did not include the effect of 4,296,920 shares of common stock issuable upon the exercise of outstanding stock options, 23,472,061 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events On April 20, 2016, the Company sold an aggregate of 9,166,667 shares of common stock and warrants to purchase 1,833,333 shares of common stock to two individual investors for an aggregate purchase price of $137,500, or $0.015 per share. The Company incurred an aggregate of $6,875 of offering costs in connection with these transactions. The warrants have a three-year term, are exercisable at $0.02 per share and were fully vested at the date of issuance. In addition, the warrants are callable by the Company in the event that the closing price of its common stock for at least fifteen trading days in any consecutive twenty-trading-day period is equal to or greater than $0.20.

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Components of Property and Equipment, on Net Basis	As of March 31, 2016 and December 31, 2015, property and equipment, on a net basis, consisted of the following: March 31, 2016 December 31, 2015 Leasehold improvements $ 328,977 $ 328,977 Equipment 520,658 515,307 849,635 844,284 Less: Accumulated depreciation (621,408 ) (598,663 ) $ 228,227 $ 245,621

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2016
Payables and Accruals [Abstract]
Components of Accrued Expenses	As of March 31, 2016 and December 31, 2015, accrued expenses consisted of the following: March 31, 2016 December 31, 2015 Accrued compensation $ 116,455 $ 116,455 Accrued interest (see Note 5) 79,267 39,188 Accrued professional fees 2,750 22,000 Accrued consulting fees and other expenses 21,827 22,250 $ 220,299 $ 199,893

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Summary of Stock Option Transactions	A summary of stock option transactions under the Equity Incentive Plans during the three months ended March 31, 2016 is set forth below: Stock Option Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2015 8,365,070 $ 0.11 $ — Granted during the period — — — Exercised during the period — — — Terminated during the period (2,000,000 ) $ 0.04 — Outstanding at March 31, 2016 6,365,070 $ 0.13 $ — Exercisable at March 31, 2016 6,115,070 $ 0.13 $ — Exercisable at December 31, 2015 6,002,570 $ 0.13 $ —
Summary of Stock Options Outstanding and Exercisable	Information with respect to stock options outstanding and stock options exercisable as of March 31, 2016 is as follows: Stock Options Outstanding Stock Options Exercisable Exercise Price Number of Shares Available Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) Number of Shares Available for Purchase Under Outstanding Stock Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) $ 0.07 2,068,150 $ 0.07 4.0 2,068,150 $ 0.07 4.0 $ 0.08 450,000 $ 0.08 8.9 200,000 $ 0.08 8.9 $ 0.10 2,180,253 $ 0.10 2.9 2,180,253 $ 0.10 2.9 $ 0.20 833,333 $ 0.20 6.0 833,333 $ 0.20 6.0 $ 0.30 833,334 $ 0.30 6.0 833,334 $ 0.30 6.0 6,365,070 $ 0.13 4.5 6,115,070 $ 0.13 4.3
Summary of Non Vested Stock Options Granted	A summary of the non-vested shares subject to stock options granted under the Equity Incentive Plans as of March 31, 2016 is as follows: Stock Option Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2015 2,362,500 $ 0.03 Granted during the period — — Vested during the period (112,500 ) $ 0.05 Terminated during the period (2,000,000 ) $ 0.03 Non-vested at March 31, 2016 250,000 $ 0.05
Summary of Warrant Transactions	A summary of warrant transactions during the three months ended March 31, 2016 is as follows: Warrant Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at December 31, 2015 25,454,701 $ 0.08 $ 3,459 Issued during the period — — — Exercised during the period — — — Terminated during the period (500,000 ) $ 0.04 — Outstanding at March 31, 2016 24,954,701 $ 0.08 $ — Exercisable at March 31, 2016 24,954,701 $ 0.08 $ — Exercisable at December 31, 2015 25,454,701 $ 0.08 $ 3,459
Summary of Warrants Outstanding and Exercisable	Information with respect to warrants outstanding and warrants exercisable at March 31, 2016 is as follows: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number of Shares Available Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share Number of Shares Available for Purchase Under Outstanding Warrants Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Per Common Share $ 0.03 - 0.04 1,167,442 2.0 $ 0.04 1,167,442 2.0 $ 0.04 $ 0.06 - 0.07 10,344,244 3.2 $ 0.07 10,344,244 3.2 $ 0.07 $ 0.08 - 0.10 13,443,015 3.8 $ 0.10 13,443,015 3.8 $ 0.10 24,954,701 3.5 $ 0.08 24,954,701 3.5 $ 0.08

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation	During the three months ended March 31, 2016 and 2015, the Company recorded stock-based compensation expense as follows: Three Months Ended March 31, 2016 2015 General and administrative $ 299 $ 187,357 Sales and marketing 1,397 131,554 Research and development — 56,177 $ 1,696 $ 375,088

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Working capital deficit	$ 643,699
Accumulated deficit	$ 25,549,186	$ 24,779,587

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory	$ 100,918	$ 103,220

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment, on Net Basis (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 328,977	$ 228,227
Equipment	520,658	515,307
Property and equipment, Gross	849,635	844,284
Less: Accumulated depreciation	(621,408)	(598,663)
Property and equipment, net	$ 228,227	$ 245,621

Accrued Expenses - Components o

Accrued Expenses - Components of Accrued Expenses (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued compensation	$ 116,455	$ 253,305
Accrued interest (see Note 9)	79,267	39,188
Accrued professional fees	2,750	22,000
Accrued consulting fees and other expenses	21,827	22,250
Accrued liabilities, total	$ 220,299	$ 199,893

Convertible Debentures (Details

Convertible Debentures (Details Narrative) - USD ($)	Aug. 21, 2012	Apr. 26, 2007	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 18, 2015	Dec. 03, 2015	Nov. 11, 2015
Debt Instrument [Line Items]
Convertible debenture outstanding principal			$ 815,605		$ 788,501
April 2007 Convertible Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount		$ 25,000
Convertible debenture, maturity date		Jan. 2, 2009
Convertible debenture, interest rate		12.00%
Convertible debenture, conversion price		$ 0.40
Common stock issued as payment on principal and interest on convertible debentures, shares		62,500
Interest expense related to convertible debenture			748	$ 740
Convertible debenture outstanding principal			25,000		25,000
Accrued and unpaid interest on convertible debt			17,189		16,441
Zanett August 2012 Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture, maturity date	Aug. 21, 2015
Common stock issued as payment on principal and interest on convertible debentures, shares	4,761,250
Interest expense related to convertible debenture			9,496	$ 9,392
Convertible debenture outstanding principal			476,125		476,125
Accrued and unpaid interest on convertible debt			$ 23,376		$ 13,880
Debenture term			3 years
2015 Debentures [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount						$ 997,222	$ 997,222	$ 997,222
Convertible debenture, interest rate			12.00%
Convertible debenture, conversion price			$ 0.07
Common stock issued as payment on principal and interest on convertible debentures, shares			14,246,029
Interest expense related to convertible debenture			$ 56,939
Convertible debenture outstanding principal			$ 788,501
Debenture term			2 years
Proceeds from private placement			$ 897,500
Percentage of original issuance discount debt			10.00%
Debt amortized discount			$ 83,596
2015 Debenture Warrants [Member]
Debt Instrument [Line Items]
Accrued and unpaid interest on convertible debt			$ 27,104
Debenture term					2 years
Number of warrants issued to purchase of common stock shares			7,123,014
Debt amortized discount			$ 99,722
Warrants exercise price per share			$ 0.10
Amortization of discount					$ 117,708
Accrued liability			$ 38,702		$ 8,867
Debt carrying value			$ 98,021
Zanett Opportunity Fund, Ltd [Member] | 8% Convertible Debenture [Member] | Zanett August 2012 Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount	$ 476,125
Convertible debenture, interest rate	8.00%
Convertible debenture, conversion price	$ 0.10

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative)	3 Months Ended
	Mar. 31, 2016USD ($)shares
Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vested period	1 year
Warrant [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vested period	3 years
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	10,000,000
Issuance of stock option to purchases of common stock shares	3,846,920
Common stock stock shares issued under plan	90,500
Number of stock option shares issued upto shares	28,622,308
2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock stock shares issued under plan	14,000,000
Number of common stock shares award under plan	2,518,150
Number of common stock shares increased under plan	31,140,458
Unrecognized compensation cost related to non-vested | $	$ 14,212
Recognized non vested over a weighted average period	26 months

Stockholders' Deficiency - Summ

Stockholders' Deficiency - Summary of Stock Option Transactions (Details)	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Equity [Abstract]
Stock Option Outstanding, Number, Beginning Balance | shares	8,365,070
Stock Option Granted during the period, Shares | shares
Stock Option Exercised during the period, Shares | shares
Stock Option Terminated during the period, Shares | shares	(2,000,000)
Stock Option Outstanding shares, Ending balance | shares	6,365,070
Stock Option Exercisable, Beginning balance | shares	6,002,570
Stock Option Exercisable, Ending balance | shares	6,115,070
Stock Option Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 0.11
Stock Option Grants in Period, Weighted Average Exercise Price
Stock Option Exercises in Period, Weighted Average Exercise Price
Stock OptionTerminated, Weighted Average Exercise Price	$ 0.04
Stock Option Outstanding, Weighted Average Exercise Price, Ending balance	0.13
Stock Option Exercisable, Weighted Average Exercise Price, Beginning balance	0.13
Stock Option Exercisable, Weighted Average Exercise Price, Ending balance	$ 0.13
Stock Option Outstanding, Aggregate Intrinsic Value, Beginning balance | $
Stock Option Granted Aggregate Intrinsic Value
Stock Option Exercised Aggregate Intrinsic Value | $
Stock Option Outstanding, Aggregate Intrinsic Value, Ending balance | $
Stock Option Exercisable, Intrinsic Value Beginning balance | $
Stock Option Exercisable, Intrinsic Value Ending balance | $

Stockholders_ Deficiency - Summ

Stockholders’ Deficiency - Summary of Stock Options Outstanding and Exercisable (Details) - $ / shares	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Available Under Outstanding Stock Options	6,365,070	8,365,070
Weighted Average Exercise Price Per Common Share	$ 0.13	$ 0.11
Weighted Average Remaining Contractual Life (Years)	4 years 6 months
Number of Shares Available for Purchase Under Outstanding Stock Options	6,115,070	6,002,570
Weighted Average Exercise Price Per Common Share	$ 0.13	$ 0.13
Weighted Average Remaining Contractual Life (Years)	4 years 3 months 18 days
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.07
Number of Shares Available Under Outstanding Stock Options	2,068,150
Weighted Average Exercise Price Per Common Share	$ 0.07
Weighted Average Remaining Contractual Life (Years)	4 years
Number of Shares Available for Purchase Under Outstanding Stock Options	2,068,150
Weighted Average Exercise Price Per Common Share	$ 0.07
Weighted Average Remaining Contractual Life (Years)	4 years
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.08
Number of Shares Available Under Outstanding Stock Options	450,000
Weighted Average Exercise Price Per Common Share	$ 0.08
Weighted Average Remaining Contractual Life (Years)	8 years 10 months 24 days
Number of Shares Available for Purchase Under Outstanding Stock Options	200,000
Weighted Average Exercise Price Per Common Share	$ 0.08
Weighted Average Remaining Contractual Life (Years)	8 years 10 months 24 days
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.10
Number of Shares Available Under Outstanding Stock Options	2,180,253
Weighted Average Exercise Price Per Common Share	$ 0.10
Weighted Average Remaining Contractual Life (Years)	2 years 10 months 24 days
Number of Shares Available for Purchase Under Outstanding Stock Options	2,180,253
Weighted Average Exercise Price Per Common Share	$ 0.10
Weighted Average Remaining Contractual Life (Years)	2 years 10 months 24 days
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.20
Number of Shares Available Under Outstanding Stock Options	833,333
Weighted Average Exercise Price Per Common Share	$ 0.20
Weighted Average Remaining Contractual Life (Years)	6 years
Number of Shares Available for Purchase Under Outstanding Stock Options	833,333
Weighted Average Exercise Price Per Common Share	$ 0.20
Weighted Average Remaining Contractual Life (Years)	6 years
Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$ 0.30
Number of Shares Available Under Outstanding Stock Options	833,334
Weighted Average Exercise Price Per Common Share	$ 0.30
Weighted Average Remaining Contractual Life (Years)	6 years
Number of Shares Available for Purchase Under Outstanding Stock Options	833,334
Weighted Average Exercise Price Per Common Share	$ 0.30
Weighted Average Remaining Contractual Life (Years)	6 years

Stockholders' Deficiency - Su28

Stockholders' Deficiency - Summary of Non Vested Stock Options Granted (Details)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Equity [Abstract]
Stock Option Nonvested, Number, Beginning Balance | shares	2,362,500
Stock Option Granted during the period | shares
Stock Option Vested during the period | shares	(112,500)
Stock Option Terminated during the period | shares	(2,000,000)
Stock Option Non-vested Balance | shares	250,000
Stock Option Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 0.03
Stock Option Weighted Average Grant Date Fair Value Per Share, Granted | $ / shares
Stock Option Weighted Average Grant Date Fair Value Per Share, Vested | $ / shares	$ 0.05
Stock Option Weighted Average Grant Date Fair Value Per Share, Terminated | $ / shares	0.03
Stock Option Weighted Average Grant Date Fair Value Per Share, Ending Balance | $ / shares	$ 0.05

Stockholders' Deficiency - Su29

Stockholders' Deficiency - Summary of Warrant Transactions (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Warrant Shares Outstanding | shares	25,454,701
Warrant Shares Issued during the period | shares
Warrant Shares Exercised during the period | shares
Warrant Shares Terminated during the period | shares	(500,000)
Warrant Shares Outstanding | shares	24,954,701
Warrant Shares Exercisable Beginning Balance | shares	25,454,701
Warrant Shares Exercisable Ending Balance | shares	24,954,701
Weighted Average Exercise Price Per Common Share Outstanding | $ / shares	$ 0.08
Weighted Average Exercise Price Per Common Share Issued during the period | $ / shares
Weighted Average Exercise Price Per Common Share Exercised during the period | $ / shares
Weighted Average Exercise Price Per Common Share Terminated during the period | $ / shares	$ 0.04
Weighted Average Exercise Price Per Common Share Outstanding | $ / shares	0.08
Weighted Average Exercise Price Per Common Share Exercisable Beginning Balance | $ / shares	0.08
Weighted Average Exercise Price Per Common Share Exercisable Ending Balance | $ / shares	$ 0.08
Aggregate Intrinsic Value Outstanding Beginning Balance | $	$ 3,459
Aggregate Intrinsic Value Issued during the period | $
Aggregate Intrinsic Value Exercised during the period | $
Aggregate Intrinsic Value Terminated during the period | $
Aggregate Intrinsic Value Outstanding Ending Balance | $
Aggregate Intrinsic Value Exercisable Beginning Balance | $	$ 3,459
Aggregate Intrinsic Value Exercisable Ending Balance | $

Stockholders' Deficiency - Su30

Stockholders' Deficiency - Summary of Warrants Outstanding and Exercisable (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Number of Shares Available Under Outstanding Stock Options/ Warrants		24,954,701
Weighted Average Remaining Contractual Life (Years)	3 years 6 months
Weighted Average Exercise Price Per Common Share		$ 0.08
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants		24,954,701
Weighted Average Remaining Contractual Life (Years)	3 years 6 months
Weighted Average Exercise Price Per Common Share		$ 0.08
Range One [Member]
Range of Exercise Prices, Lower Limit		0.03
Range of Exercise Prices, Upper Limit		$ 0.04
Number of Shares Available Under Outstanding Stock Options/ Warrants		1,167,442
Weighted Average Remaining Contractual Life (Years)		2 years
Weighted Average Exercise Price Per Common Share		$ 0.04
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants		1,167,442
Weighted Average Remaining Contractual Life (Years)		2 years
Weighted Average Exercise Price Per Common Share		$ 0.04
Range Two [Member]
Range of Exercise Prices, Lower Limit		0.06
Range of Exercise Prices, Upper Limit		$ 0.07
Number of Shares Available Under Outstanding Stock Options/ Warrants		10,344,244
Weighted Average Remaining Contractual Life (Years)		3 years 2 months 12 days
Weighted Average Exercise Price Per Common Share		$ 0.07
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants		10,344,244
Weighted Average Remaining Contractual Life (Years)		3 years 2 months 12 days
Weighted Average Exercise Price Per Common Share		$ 0.07
Range Three [Member]
Range of Exercise Prices, Lower Limit		0.08
Range of Exercise Prices, Upper Limit		$ 0.10
Number of Shares Available Under Outstanding Stock Options/ Warrants		13,443,015
Weighted Average Remaining Contractual Life (Years)		3 years 9 months 18 days
Weighted Average Exercise Price Per Common Share		$ 0.10
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants		13,443,015
Weighted Average Remaining Contractual Life (Years)		3 years 9 months 18 days
Weighted Average Exercise Price Per Common Share		$ 0.10

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock-based compensation expense related to stock options and warrants	$ 1,696	$ 375,088
Employees and Director [Member]
Stock-based compensation expense related to stock options and warrants	$ 1,696	$ 375,088

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1,696	$ 375,088
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	299	187,357
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1,397	131,554
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense		$ 56,177

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Outstanding Stock Options [Member]
Anti-dilutive	6,365,070	4,296,920
Outstanding Warrants [Member]
Anti-dilutive	24,954,701	23,472,061
Conversion of Convertible Debt [Member]
Anti-dilutive	19,069,779	4,823,750

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Apr. 20, 2016USD ($)$ / sharesshares
Aggregate number of shares sold during period | shares	9,166,667
Warrants issued to purchase number of common stock | shares	1,833,333
Aggregate purchase price | $	$ 137,500
Shares issued, per share | $ / shares	$ 0.015
Offering costs in connection with these transactions | $	$ 6,875
Warrants term	3 years
Warrants exercisable price per share | $ / shares	$ 0.20